Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...
Wag! Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder Value
Adjusted EBITDA 1 loss of $1.0 million, compared to breakeven Adjusted EBITDA loss in the fourth quarter of 2023. Revenues decreased 16% to $70.5 million, compared to $83.9 million in 2023 – comprised ...